- $581.07m
- $528.01m
- $52.23m
Brief: Brainsway Announces Final Local Coverage Determination Issued By Regional Medicare Administrative Contractor
Brief: Brainsway Announces Addition Of Markus Heilig To Scientific Advisory Board
Brief: Brainsway Announces Multiple Publications Of New Real-World OCD Data For Its Deep TMS System
Brief: BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects
Brief: Brainsway Reports Q3 Loss Per Share $0.05
Brief: Brainsway Ltd Files For Mixed Shelf Of Up To $100 Million
U.S. STOCKS ON THE MOVE-Tesla, ViacomCBS, Pfizer
BrainsWay Ltd gains after FDA approves device for reducing anxiety in patients with depression
Brief: FDA Clears Brainsway Deep Tms™ System For Decreasing Anxiety Symptoms In Depressed Patients
Brief: Brainsway Reports Q2 Results
Brief: BrainsWay Announces Positive Ocd Coverage Policy By Blue Cross Blue Shield® Licensee HCSC
Brief: BrainsWay Says Centene Published Positive Coverage Policy For Treatment Of OCD Using BrainsWay Deep TMS System
Brief: Brainsway Reports Q1 Revenues Of $6.1 Mln
Brief: BrainsWay Appoints R. Scott Areglado As CFO
Brief: BrainsWay Announces Launch Of Noninvasive Treatment For Smoking Addiction To U.S. Providers
Brief: Brainsway Receives FDA Clearance For Three-Minute Theta Burst Treatment Protocol For Major Depressive Disorder
Brief: Brainsway Reports Fourth Quarter And Full-Year 2020 Financial Results And Operational Highlights
NASDAQ RESUMED AT 09:15 AM
Brief: Brainsway Ltd Announces Pricing Of $39,287,000 Underwritten Offering Of American Depositary Shares